Hypernegative GABAA Reversal Potential in Pyramidal Cells Contributes to Medial Prefrontal Cortex Deactivation in a Mouse Model of Neuropathic Pain
The Journal of Pain · 2024
DOI: 10.1016/j.jpain.2023.09.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pain, 2024. Verfasst von Haram R Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Hauptthemen laut MEDLINE: Chronic Pain, Neuralgia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NIDA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Deactivation of the medial prefrontal cortex (mPFC) has been broadly reported in both neuropathic pain models and human chronic pain patients. Several cellular mechanisms may contribute to the inhibition of mPFC activity, including enhanced GABAergic inhibition. The functional effect of GABAA(γ-aminobutyric acid type A)-receptor activation depends on the concentration of intracellular chloride in the postsynaptic neuron, which is mainly regulated by the activity of Na-K-2Cl cotransporter isoform 1 (NKCC1) and K-Cl cotransporter isoform 2 (KCC2), 2 potassium-chloride cotransporters that import and extrude chloride, respectively. Recent work has shown that the NKCC1-KCC2 ratio is affected in numerous pathological conditions, and we hypothesized that it may contribute to the alteration of mPFC function in neuropathic pain. We used quantitative in situ hybridization to assess the level of expression of NKCC1 and KCC2 in the mPFC of a mouse model of neuropathic pain (spared nerve injury), and we found that KCC2 transcript is increased in the mPFC of spared nerve injury mice while NKCC1 is not affected. Perforated patch recordings further showed that this results in the hypernegative reversal potential of the GABAA current in pyramidal neurons of the mPFC. Computational simulations suggested that this change in GABAA reversal potential is sufficient to significantly reduce the overall activity of the cortical network. Thus, our results identify a novel pathological modulation of GABAA function and a new mechanism by which mPFC function is inhibited in neuropathic pain. Our data also help explain previous findings showing that activation of mPFC interneurons has proalgesic effect in neuropathic, but not in control conditions. PERSPECTIVE: Chronic pain is associated with the presence of depolarizing GABAA current in the spinal cord, suggesting that pharmacological NKCC1 antagonism has analgesic effects. However, our results show that in neuropathic pain, GABAA current is actually hyperinhibitory in the mPFC, where it contributes to the mPFC functional deactivation. This suggests caution in the use of NKCC1 antagonism to treat pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Förderung
- NIMH NIH HHS
- NIDA NIH HHS
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Kim, H. R., Long, M., Sekerková, G., Maes, A., Kennedy, A., & Martina, M. (2024). Hypernegative GABAA Reversal Potential in Pyramidal Cells Contributes to Medial Prefrontal Cortex Deactivation in a Mouse Model of Neuropathic Pain. The Journal of Pain. https://doi.org/10.1016/j.jpain.2023.09.021
Vancouver
Kim HR, Long M, Sekerková G, Maes A, Kennedy A, Martina M. Hypernegative GABAA Reversal Potential in Pyramidal Cells Contributes to Medial Prefrontal Cortex Deactivation in a Mouse Model of Neuropathic Pain. The Journal of Pain. 2024. doi:10.1016/j.jpain.2023.09.021
BibTeX
@article{Kim2024,
author = {Kim, Haram R and Long, Manzhao and Sekerková, Gabriella and Maes, Amadeus and Kennedy, Ann and Martina, Marco},
title = {Hypernegative GABAA Reversal Potential in Pyramidal Cells Contributes to Medial Prefrontal Cortex Deactivation in a Mouse Model of Neuropathic Pain},
journal = {The Journal of Pain},
year = {2024},
doi = {10.1016/j.jpain.2023.09.021}
}
EUVIMED